Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327639
Status:
UNKNOWN
Last Update Posted:
2006-05-18
First Post:
2006-05-17
Brief Title:
Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto
Status:
UNKNOWN
Status Verified Date:
2005-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years with improvements in transfusion therapy and introduction of iron chelation therapy Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life with fertility and childbearing becoming important issues Data regarding this important topic remain limited without clear data regarding iron control including serial assessment of hepatic iron concentration the need for assistance in becoming pregnant and use of iron chelating agents during pregnancy As the life expectancy increases and overall health improves in thalassemia clear data on fertility pregnancy complications and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care quality of life and patient expectations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None